GLP-1 receptor agonists like semaglutide and tirzepatide consistently reduce both fat and lean muscle mass during weight loss, creating a paradox that may undermine their cardiovascular benefits. The muscle loss stems from caloric restriction, anabolic resistance, and hormonal changes that collectively promote muscle catabolism alongside the intended fat reduction. This represents a critical blind spot in obesity treatment. Muscle mass is fundamental to metabolic health, insulin sensitivity, and cardiovascular resilience. When muscle declines, patients face increased risks of sarcopenia, frailty, and metabolic dysfunction that could negate the heart-protective effects of weight loss. The field is responding with combination approaches: myostatin inhibitors and selective androgen receptor modulators show promise for preserving muscle during GLP-1 therapy. Resistance training remains the gold standard intervention, while optimized protein intake and specific nutraceuticals offer additional protection. This analysis signals a paradigm shift from pursuing maximum weight loss to achieving "high-quality" weight loss that maintains muscle mass. The implications are profound for the millions now using these medications, suggesting current treatment protocols may be suboptimal for long-term cardiovascular protection.